Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX

1.

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. https://doi.org/10.1126/science.1160809CrossRefPubMedPubMedCentral

2.

Levine, A. J., & Puzio-Kuter, A. M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 330(6009), 1340–1344. https://doi.org/10.1126/science.1193494CrossRefPubMed

3.

Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016). Oncogene-directed alterations in cancer cell metabolism. Trends Cancer, 2(7), 365–377. https://doi.org/10.1016/j.trecan.2016.06.002CrossRefPubMedPubMedCentral

4.

Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E., & Dang, C. V. (2015). MYC and metabolism on the path to cancer. Seminars in Cell & Developmental Biology, 43, 11–21. https://doi.org/10.1016/j.semcdb.2015.08.003CrossRef

5.

Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021). The metabolic landscape of RAS-driven cancers from biology to therapy. Nat Cancer, 2(3), 271–283. https://doi.org/10.1038/s43018-021-00184-xCrossRefPubMedPubMedCentral

6.

Schulze, A., & Harris, A. L. (2012). How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature, 491(7424), 364–373. https://doi.org/10.1038/nature11706CrossRefPubMed

7.

Sciacovelli, M., & Frezza, C. (2016). Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radical Biology & Medicine, 100, 175–181. https://doi.org/10.1016/j.freeradbiomed.2016.04.025CrossRef

8.

Schmidt, C., Sciacovelli, M., & Frezza, C. (2020). Fumarate hydratase in cancer: A multifaceted tumour suppressor. Seminars in Cell & Developmental Biology, 98, 15–25. https://doi.org/10.1016/j.semcdb.2019.05.002CrossRef

9.

Lloyd, M. C., Cunningham, J. J., Bui, M. M., Gillies, R. J., Brown, J. S., & Gatenby, R. A. (2016). Darwinian dynamics of intratumoral heterogeneity: Not solely random mutations but also variable environmental selection forces. Cancer Research, 76(11), 3136–3144. https://doi.org/10.1158/0008-5472.CAN-15-2962CrossRefPubMedPubMedCentral

10.

Gillies, R. J., Brown, J. S., Anderson, A. R. A., & Gatenby, R. A. (2018). Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow. Nature Reviews Cancer, 18(9), 576–585. https://doi.org/10.1038/s41568-018-0030-7CrossRefPubMedPubMedCentral

11.

Elia, I., & Haigis, M. C. (2021). Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism. Nature Metabolism, 3(1), 21–32. https://doi.org/10.1038/s42255-020-00317-zCrossRefPubMedPubMedCentral

12.

Harris, A. L. (2002). Hypoxia–A key regulatory factor in tumour growth. Nature Reviews Cancer, 2(1), 38–47. https://doi.org/10.1038/nrc704CrossRefPubMed

13.

Ratcliffe, P. J. (2013). Oxygen sensing and hypoxia signalling pathways in animals: The implications of physiology for cancer. Journal of Physiology, 591(8), 2027–2042. https://doi.org/10.1113/jphysiol.2013.251470CrossRefPubMedPubMedCentral

14.

Semenza, G. L. (2012). Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends in Pharmacological Sciences, 33(4), 207–214. https://doi.org/10.1016/j.tips.2012.01.005CrossRefPubMedPubMedCentral

15.

Wouters, B. G., & Koritzinsky, M. (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Reviews Cancer, 8(11), 851–864. https://doi.org/10.1038/nrc2501CrossRefPubMed

16.

Sebestyen, A., Kopper, L., Danko, T., & Timar, J. (2021). Hypoxia signaling in cancer: From basics to clinical practice. Pathology Oncology Research, 27, 1609802. https://doi.org/10.3389/pore.2021.1609802CrossRefPubMedPubMedCentral

17.

Li, F., & Simon, M. C. (2020). Cancer cells don’t live alone: Metabolic communication within tumor microenvironments. Developmental Cell, 54(2), 183–195. https://doi.org/10.1016/j.devcel.2020.06.018CrossRefPubMedPubMedCentral

18.

Corbet, C., & Feron, O. (2017). Tumour acidosis: From the passenger to the driver’s seat. Nature Reviews Cancer, 17(10), 577–593. https://doi.org/10.1038/nrc.2017.77CrossRefPubMed

19.

Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation, 118(12), 3930–3942. https://doi.org/10.1172/JCI36843CrossRefPubMedPubMedCentral

20.

Payen, V. L., Mina, E., Van Hee, V. F., Porporato, P. E., & Sonveaux, P. (2020). Monocarboxylate transporters in cancer. Mol Metab, 33, 48–66. https://doi.org/10.1016/j.molmet.2019.07.006CrossRefPubMed

21.

Swietach, P. (2019). What is pH regulation, and why do cancer cells need it? Cancer and Metastasis Reviews, 38(1–2), 5–15. https://doi.org/10.1007/s10555-018-09778-xCrossRefPubMed

22.

Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011). Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Molecular Pharmaceutics, 8(6), 2032–2038. https://doi.org/10.1021/mp200292cCrossRefPubMedPubMedCentral

23.

Schonichen, A., Webb, B. A., Jacobson, M. P., & Barber, D. L. (2013). Considering protonation as a posttranslational modification regulating protein structure and function. Annual Review of Biophysics, 42, 289–314. https://doi.org/10.1146/annurev-biophys-050511-102349CrossRefPubMedPubMedCentral

24.

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042CrossRefPubMedPubMedCentral

25.

Chafe, S. C., Vizeacoumar, F. S., Venkateswaran, G., Nemirovsky, O., Awrey, S., Brown, W. S., et al. (2021). Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv, 7(35). https://doi.org/10.1126/sciadv.abj0364.

26.

Korenchan, D. E., & Flavell, R. R. (2019). Spatiotemporal pH heterogeneity as a promoter of cancer progression and therapeutic resistance. Cancers (Basel), 11(7). https://doi.org/10.3390/cancers11071026.

27.

Mason, J. A., Hagel, K. R., Hawk, M. A., & Schafer, Z. T. (2017). Metabolism during ECM detachment: Achilles heel of cancer cells? Trends Cancer, 3(7), 475–481. https://doi.org/10.1016/j.trecan.2017.04.009CrossRefPubMed

28.

Sciacovelli, M., & Frezza, C. (2017). Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS Journal, 284(19), 3132–3144. https://doi.org/10.1111/febs.14090CrossRefPubMed

29.

Mosier, J. A., Schwager, S. C., Boyajian, D. A., & Reinhart-King, C. A. (2021). Cancer cell metabolic plasticity in migration and metastasis. Clinical & Experimental Metastasis, 38(4), 343–359. https://doi.org/10.1007/s10585-021-10102-1CrossRef

30.

Chen, Y., McAndrews, K. M., & Kalluri, R. (2021). Clinical and therapeutic relevance of cancer-associated fibroblasts. Nature Reviews. Clinical Oncology. https://doi.org/10.1038/s41571-021-00546-5CrossRefPubMedPubMedCentral

31.

Fiaschi, T., Marini, A., Giannoni, E., Taddei, M. L., Gandellini, P., De Donatis, A., et al. (2012). Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Research, 72(19), 5130–5140. https://doi.org/10.1158/0008-5472.CAN-12-1949CrossRefPubMed

32.

Hulikova, A., & Swietach, P. (2014). Rapid CO2 permeation across biological membranes: Implications for CO2 venting from tissue. The FASEB Journal, 28(7), 2762–2774. https://doi.org/10.1096/fj.13-241752CrossRefPubMed

33.

Rohani, N., Hao, L., Alexis, M. S., Joughin, B. A., Krismer, K., Moufarrej, M. N., et al. (2019). Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes. Cancer Research, 79(8), 1952–1966. https://doi.org/10.1158/0008-5472.CAN-18-1604CrossRefPubMedPubMedCentral

34.

Chiche, J., Brahimi-Horn, M. C., & Pouyssegur, J. (2010). Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. Journal of Cellular and Molecular Medicine, 14(4), 771–794. https://doi.org/10.1111/j.1582-4934.2009.00994.xCrossRefPubMed

35.

Reshkin, S. J., Greco, M. R., & Cardone, R. A. (2014). Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philosophical Transactions of the Royal Society of London. Series B, Biological sciences, 369(1638), 20130100. https://doi.org/10.1098/rstb.2013.0100CrossRefPubMedPubMedCentral

36.

Parks, S. K., Chiche, J., & Pouyssegur, J. (2011). pH control mechanisms of tumor survival and growth. Journal of Cellular Physiology, 226(2), 299–308. https://doi.org/10.1002/jcp.22400CrossRefPubMed

37.

Fang, J. S., Gillies, R. D., & Gatenby, R. A. (2008). Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Seminars in Cancer Biology, 18(5), 330–337. https://doi.org/10.1016/j.semcancer.2008.03.011CrossRefPubMedPubMedCentral

38.

Gillies, R. J. (2021). Cancer heterogeneity and metastasis: Life at the edge. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-021-10101-2CrossRef

39.

Pastorek, J., Pastorekova, S., Callebaut, I., Mornon, J. P., Zelnik, V., Opavsky, R., et al. (1994). Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene, 9(10), 2877–2888.PubMed

40.

Opavsky, R., Pastorekova, S., Zelnik, V., Gibadulinova, A., Stanbridge, E. J., Zavada, J., et al. (1996). Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics, 33(3), 480–487. https://doi.org/10.1006/geno.1996.0223CrossRefPubMed

41.

Innocenti, A., Pastorekova, S., Pastorek, J., Scozzafava, A., De Simone, G., & Supuran, C. T. (2009). The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorganic & Medicinal Chemistry Letters, 19(20), 5825–5828. https://doi.org/10.1016/j.bmcl.2009.08.088CrossRef

42.

Mahon, B. P., Bhatt, A., Socorro, L., Driscoll, J. M., Okoh, C., Lomelino, C. L., et al. (2016). The structure of carbonic anhydrase IX is adapted for low-pH catalysis. Biochemistry, 55(33), 4642–4653. https://doi.org/10.1021/acs.biochem.6b00243CrossRefPubMed

43.

Wykoff, C. C., Beasley, N. J., Watson, P. H., Turner, K. J., Pastorek, J., Sibtain, A., et al. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Research, 60(24), 7075–7083.PubMed

44.

Ditte, P., Dequiedt, F., Svastova, E., Hulikova, A., Ohradanova-Repic, A., Zatovicova, M., et al. (2011). Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Research, 71(24), 7558–7567. https://doi.org/10.1158/0008-5472.CAN-11-2520CrossRefPubMed

45.

McDonald, P. C., Chafe, S. C., Brown, W. S., Saberi, S., Swayampakula, M., Venkateswaran, G., et al. (2019). Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology, 157(3), 823–837. https://doi.org/10.1053/j.gastro.2019.05.004CrossRefPubMed

46.

Takacova, M., Holotnakova, T., Barathova, M., Pastorekova, S., Kopacek, J., & Pastorek, J. (2010). Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor 1. Oncology Reports, 23(3), 869–874.PubMed

47.

Takacova, M., Bullova, P., Simko, V., Skvarkova, L., Poturnajova, M., Feketeova, L., et al. (2014). Expression pattern of carbonic anhydrase IX in Medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway. American Journal of Pathology, 184(4), 953–965. https://doi.org/10.1016/j.ajpath.2014.01.002CrossRefPubMed

48.

Panisova, E., Kery, M., Sedlakova, O., Brisson, L., Debreova, M., Sboarina, M., et al. (2017). Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget, 8(44), 77819–77835. https://doi.org/10.18632/oncotarget.20836CrossRefPubMedPubMedCentral

49.

Kappler, M., Pabst, U., Weinholdt, C., Taubert, H., Rot, S., Kaune, T., et al. (2019). Causes and consequences of a glutamine induced normoxic HIF1 Activity for the tumor metabolism. Int J Mol Sci, 20(19). https://doi.org/10.3390/ijms20194742.

50.

Svastova, E., Hulikova, A., Rafajova, M., Zat’ovicova, M., Gibadulinova, A., Casini, A., et al. (2004). Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Letters, 577(3), 439–445. https://doi.org/10.1016/j.febslet.2004.10.043CrossRefPubMed

51.

Swietach, P., Patiar, S., Supuran, C. T., Harris, A. L., & Vaughan-Jones, R. D. (2009). The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. Journal of Biological Chemistry, 284(30), 20299–20310. https://doi.org/10.1074/jbc.M109.006478CrossRefPubMedPubMedCentral

52.

Lee, S. H., McIntyre, D., Honess, D., Hulikova, A., Pacheco-Torres, J., Cerdan, S., et al. (2018). Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo. British Journal of Cancer, 119(5), 622–630. https://doi.org/10.1038/s41416-018-0216-5CrossRefPubMedPubMedCentral

53.

Morgan, P. E., Pastorekova, S., Stuart-Tilley, A. K., Alper, S. L., & Casey, J. R. (2007). Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. American Journal of Physiology. Cell Physiology, 293(2), C738-748. https://doi.org/10.1152/ajpcell.00157.2007CrossRefPubMed

54.

Svastova, E., Witarski, W., Csaderova, L., Kosik, I., Skvarkova, L., Hulikova, A., et al. (2012). Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. Journal of Biological Chemistry, 287(5), 3392–3402. https://doi.org/10.1074/jbc.M111.286062CrossRefPubMed

55.

Orlowski, A., De Giusti, V. C., Morgan, P. E., Aiello, E. A., & Alvarez, B. V. (2012). Binding of carbonic anhydrase IX to extracellular loop 4 of the NBCe1 Na+/HCO3- cotransporter enhances NBCe1-mediated HCO3- influx in the rat heart. American Journal of Physiology. Cell Physiology, 303(1), C69-80. https://doi.org/10.1152/ajpcell.00431.2011CrossRefPubMed

56.

Jamali, S., Klier, M., Ames, S., Barros, L. F., McKenna, R., Deitmer, J. W., et al. (2015). Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Science and Reports, 5, 13605. https://doi.org/10.1038/srep13605CrossRef

57.

Ames, S., Pastorekova, S., & Becker, H. M. (2018). The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells. Oncotarget, 9(46), 27940–27957. https://doi.org/10.18632/oncotarget.25371CrossRefPubMedPubMedCentral

58.

Ames, S., Andring, J. T., McKenna, R., & Becker, H. M. (2019). CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells. Oncogene. https://doi.org/10.1038/s41388-019-1098-6CrossRefPubMed

59.

Liskova, V., Hudecova, S., Lencesova, L., Iuliano, F., Sirova, M., Ondrias, K., et al. (2019). Type 1 sodium calcium exchanger forms a complex with carbonic anhydrase IX and via reverse mode activity contributes to pH control in hypoxic tumors. Cancers (Basel), 11(8). https://doi.org/10.3390/cancers11081139.

60.

Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S., et al. (2019). Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunology Research, 7(7), 1064–1078. https://doi.org/10.1158/2326-6066.CIR-18-0657CrossRefPubMed

61.

Chiche, J., Ilc, K., Laferriere, J., Trottier, E., Dayan, F., Mazure, N. M., et al. (2009). Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Research, 69(1), 358–368. https://doi.org/10.1158/0008-5472.CAN-08-2470CrossRefPubMed

62.

McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., et al. (2016). Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research, 76(13), 3744–3755. https://doi.org/10.1158/0008-5472.CAN-15-1862CrossRefPubMed

63.

Parks, S. K., Cormerais, Y., Durivault, J., & Pouyssegur, J. (2017). Genetic disruption of the pHi-regulating proteins Na+/H+ exchanger 1 (SLC9A1) and carbonic anhydrase 9 severely reduces growth of colon cancer cells. Oncotarget, 8(6), 10225–10237. https://doi.org/10.18632/oncotarget.14379CrossRefPubMed

64.

Pacchiano, F., Carta, F., McDonald, P. C., Lou, Y., Vullo, D., Scozzafava, A., et al. (2011). Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. Journal of Medicinal Chemistry, 54(6), 1896–1902. https://doi.org/10.1021/jm101541xCrossRefPubMed

65.

Lock, F. E., McDonald, P. C., Lou, Y., Serrano, I., Chafe, S. C., Ostlund, C., et al. (2013). Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene, 32(44), 5210–5219. https://doi.org/10.1038/onc.2012.550CrossRefPubMed

66.

Ledaki, I., McIntyre, A., Wigfield, S., Buffa, F., McGowan, S., Baban, D., et al. (2015). Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget, 6(23), 19413–19427. https://doi.org/10.18632/oncotarget.4989CrossRefPubMedPubMedCentral

67.

Neri, D., & Supuran, C. T. (2011). Interfering with pH regulation in tumours as a therapeutic strategy. Nature Reviews Drug Discovery, 10(10), 767–777. https://doi.org/10.1038/nrd3554CrossRefPubMed

68.

Pastorek, J., & Pastorekova, S. (2015). Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Seminars in Cancer Biology, 31, 52–64. https://doi.org/10.1016/j.semcancer.2014.08.002CrossRefPubMed

69.

Strapcova, S., Takacova, M., Csaderova, L., Martinelli, P., Lukacikova, L., Gal, V., et al. (2020). Clinical and pre-clinical evidence of carbonic anhydrase IX in pancreatic cancer and its high expression in pre-cancerous lesions. Cancers (Basel), 12(8). https://doi.org/10.3390/cancers12082005.

70.

Kery, M., Oravcova, N., Radenkovic, S., Iuliano, F., Tomaskova, J., & Golias, T. (2018). Pyruvate dehydrogenase kinase 1 and carbonic anhydrase IX targeting in hypoxic tumors. Neoplasma, 66(1), 63–72. https://doi.org/10.4149/neo_2018_180531N357CrossRefPubMed

71.

Gibadulinova, A., Bullova, P., Strnad, H., Pohlodek, K., Jurkovicova, D., Takacova, M., et al. (2020). CAIX-mediated control of LIN28/let-7 axis contributes to metabolic adaptation of breast cancer cells to hypoxia. International Journal of Molecular Sciences, 21, 19. https://doi.org/10.3390/ijms21124299CrossRef

72.

Benej, M., Svastova, E., Banova, R., Kopacek, J., Gibadulinova, A., Kery, M., et al. (2020). CA IX stabilizes intracellular pH to maintain metabolic reprogramming and proliferation in hypoxia. Frontiers in Oncology, 10, 1462. https://doi.org/10.3389/fonc.2020.01462CrossRefPubMedPubMedCentral

73.

Becker, H. M. (2020). Carbonic anhydrase IX and acid transport in cancer. British Journal of Cancer, 122(2), 157–167. https://doi.org/10.1038/s41416-019-0642-zCrossRefPubMed

74.

Harguindey, S., Arranz, J. L., Polo Orozco, J. D., Rauch, C., Fais, S., Cardone, R. A., et al. (2013). Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs–An integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. Journal of Translational Medicine, 11, 282. https://doi.org/10.1186/1479-5876-11-282CrossRefPubMedPubMedCentral

75.

Lamonte, G., Tang, X., Chen, J. L., Wu, J., Ding, C. K., Keenan, M. M., et al. (2013). Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. Cancer Metab, 1(1), 23. https://doi.org/10.1186/2049-3002-1-23CrossRefPubMedPubMedCentral

76.

Svastova, E., & Pastorekova, S. (2013). Carbonic anhydrase IX: A hypoxia-controlled “catalyst” of cell migration. Cell Adhesion & Migration, 7(2), 226–231. https://doi.org/10.4161/cam.23257CrossRef

77.

McDonald, P. C., Swayampakula, M., & Dedhar, S. (2018). Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites, 8(1). https://doi.org/10.3390/metabo8010020.

78.

Csaderova, L., Debreova, M., Radvak, P., Stano, M., Vrestiakova, M., Kopacek, J., et al. (2013). The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Frontiers in Physiology, 4, 271. https://doi.org/10.3389/fphys.2013.00271CrossRefPubMedPubMedCentral

79.

Radvak, P., Repic, M., Svastova, E., Takacova, M., Csaderova, L., Strnad, H., et al. (2013). Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncology Reports, 29(3), 1147–1153. https://doi.org/10.3892/or.2013.2226CrossRefPubMed

80.

Svastova, E., Zilka, N., Zat’ovicova, M., Gibadulinova, A., Ciampor, F., Pastorek, J., et al. (2003). Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Experimental Cell Research, 290(2), 332–345. https://doi.org/10.1016/s0014-4827(03)00351-3CrossRefPubMed

81.

Debreova, M., Csaderova, L., Burikova, M., Lukacikova, L., Kajanova, I., Sedlakova, O., et al. (2019). CAIX regulates invadopodia formation through both a pH-dependent mechanism and interplay with actin regulatory proteins. Int J Mol Sci, 20(11). https://doi.org/10.3390/ijms20112745.

82.

Swayampakula, M., McDonald, P. C., Vallejo, M., Coyaud, E., Chafe, S. C., Westerback, A., et al. (2017). The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene, 36(45), 6244–6261. https://doi.org/10.1038/onc.2017.219CrossRefPubMedPubMedCentral

83.

Venkateswaran, G., & Dedhar, S. (2020). Interplay of carbonic anhydrase IX with amino acid and acid/base transporters in the hypoxic tumor microenvironment. Front Cell Dev Biol, 8, 602668. https://doi.org/10.3389/fcell.2020.602668CrossRefPubMedPubMedCentral

84.

Stock, C., & Schwab, A. (2009). Protons make tumor cells move like clockwork. Pflugers Archiv. European Journal of Physiology, 458(5), 981–992. https://doi.org/10.1007/s00424-009-0677-8CrossRefPubMed

85.

LeBleu, V. S., O'Connell, J. T., Gonzalez Herrera, K. N., Wikman, H., Pantel, K., Haigis, M. C., et al. (2014). PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol, 16(10), 992–1003, 1001–1015. https://doi.org/10.1038/ncb3039.

86.

Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., et al. (2015). Metabolic reprogramming during TGFbeta1-induced epithelial-to-mesenchymal transition. Oncogene, 34(30), 3908–3916. https://doi.org/10.1038/onc.2014.321CrossRefPubMed

87.

Hui, E. P., Chan, A. T., Pezzella, F., Turley, H., To, K. F., Poon, T. C., et al. (2002). Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research, 8(8), 2595–2604.PubMed

88.

Tomes, L., Emberley, E., Niu, Y., Troup, S., Pastorek, J., Strange, K., et al. (2003). Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Research and Treatment, 81(1), 61–69. https://doi.org/10.1023/A:1025476722493CrossRefPubMed

89.

Rademakers, S. E., Lok, J., van der Kogel, A. J., Bussink, J., & Kaanders, J. H. (2011). Metabolic markers in relation to hypoxia; Staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer, 11, 167. https://doi.org/10.1186/1471-2407-11-167CrossRefPubMedPubMedCentral

90.

Mayer, A., Schneider, F., Vaupel, P., Sommer, C., & Schmidberger, H. (2012). Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. International Journal of Oncology, 41(4), 1260–1270. https://doi.org/10.3892/ijo.2012.1555CrossRefPubMedPubMedCentral

91.

Rohan, S. M., Xiao, Y., Liang, Y., Dudas, M. E., Al-Ahmadie, H. A., Fine, S. W., et al. (2011). Clear-cell papillary renal cell carcinoma: Molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Modern Pathology, 24(9), 1207–1220. https://doi.org/10.1038/modpathol.2011.80CrossRefPubMed

92.

Ord, J. J., Streeter, E. H., Roberts, I. S., Cranston, D., & Harris, A. L. (2005). Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. British Journal of Cancer, 93(3), 346–354. https://doi.org/10.1038/sj.bjc.6602666CrossRefPubMedPubMedCentral

93.

Airley, R. E., Loncaster, J., Raleigh, J. A., Harris, A. L., Davidson, S. E., Hunter, R. D., et al. (2003). GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. International Journal of Cancer, 104(1), 85–91. https://doi.org/10.1002/ijc.10904CrossRefPubMed

94.

Dooms, C., van Baardwijk, A., Verbeken, E., van Suylen, R. J., Stroobants, S., De Ruysscher, D., et al. (2009). Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: Prognostic value of positron emission tomography in early-stage non-small cell lung cancer. Journal of Thoracic Oncology, 4(7), 822–828. https://doi.org/10.1097/JTO.0b013e3181a97df7CrossRefPubMed

95.

Koukourakis, M. I., Pitiakoudis, M., Giatromanolaki, A., Tsarouha, A., Polychronidis, A., Sivridis, E., et al. (2006). Oxygen and glucose consumption in gastrointestinal adenocarcinomas: Correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Science, 97(10), 1056–1060. https://doi.org/10.1111/j.1349-7006.2006.00298.xCrossRefPubMed

96.

Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021). Metabolomics in cancer research and emerging applications in clinical oncology. CA: A Cancer Journal for Clinicians, 71(4), 333–358. https://doi.org/10.3322/caac.21670CrossRef

97.

Muir, A., Danai, L. V., & Vander Heiden, M. G. (2018). Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Dis Model Mech, 11(8). https://doi.org/10.1242/dmm.035758.

98.

Bjorling, E., & Uhlen, M. (2008). Antibodypedia, a portal for sharing antibody and antigen validation data. Molecular and Cellular Proteomics, 7(10), 2028–2037. https://doi.org/10.1074/mcp.M800264-MCP200CrossRefPubMed

99.

Helsby, M. A., Leader, P. M., Fenn, J. R., Gulsen, T., Bryant, C., Doughton, G., et al. (2014). CiteAb: A searchable antibody database that ranks antibodies by the number of times they have been cited. BMC Cell Biology, 15, 6. https://doi.org/10.1186/1471-2121-15-6CrossRefPubMedPubMedCentral

100.

van Kuijk, S. J., Yaromina, A., Houben, R., Niemans, R., Lambin, P., & Dubois, L. J. (2016). Prognostic significance of carbonic anhydrase IX expression in cancer patients: A meta-analysis. Frontiers in Oncology, 6, 69. https://doi.org/10.3389/fonc.2016.00069CrossRefPubMedPubMedCentral

101.

Weller, M. G. (2018). Ten Basic Rules of Antibody Validation. Analytical Chemistry Insights, 13, 1177390118757462. https://doi.org/10.1177/1177390118757462CrossRefPubMedPubMedCentral

102.

Dungwa, J. V., Hunt, L. P., & Ramani, P. (2012). Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Human Pathology, 43(10), 1651–1660. https://doi.org/10.1016/j.humpath.2011.12.006CrossRefPubMed

103.

Korkolopoulou, P., Perdiki, M., Thymara, I., Boviatsis, E., Agrogiannis, G., Kotsiakis, X., et al. (2007). Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol, 38(4), 629–638. https://doi.org/10.1016/j.humpath.2006.07.020CrossRefPubMed

104.

Ameis, H. M., Drenckhan, A., Freytag, M., Izbicki, J. R., Supuran, C. T., Reinshagen, K., et al. (2016). Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(3), 404–409. https://doi.org/10.3109/14756366.2015.1029471CrossRefPubMed

105.

Jarvela, S., Parkkila, S., Bragge, H., Kahkonen, M., Parkkila, A. K., Soini, Y., et al. (2008). Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer, 8, 1. https://doi.org/10.1186/1471-2407-8-1CrossRefPubMedPubMedCentral

106.

Nordfors, K., Haapasalo, J., Korja, M., Niemela, A., Laine, J., Parkkila, A. K., et al. (2010). The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: An association of CA IX with poor prognosis. BMC Cancer, 10, 148. https://doi.org/10.1186/1471-2407-10-148CrossRefPubMedPubMedCentral

107.

Haapasalo, J. A., Nordfors, K. M., Hilvo, M., Rantala, I. J., Soini, Y., Parkkila, A. K., et al. (2006). Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clinical Cancer Research, 12(2), 473–477. https://doi.org/10.1158/1078-0432.CCR-05-0848CrossRefPubMed

108.

Erpolat, O. P., Gocun, P. U., Akmansu, M., Ozgun, G., & Akyol, G. (2013). Hypoxia-related molecules HIF-1alpha, CA9, and osteopontin: Predictors of survival in patients with high-grade glioma. Strahlentherapie und Onkologie, 189(2), 147–154. https://doi.org/10.1007/s00066-012-0262-5CrossRefPubMed

109.

Proescholdt, M. A., Merrill, M. J., Stoerr, E. M., Lohmeier, A., Pohl, F., & Brawanski, A. (2012). Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro-Oncology, 14(11), 1357–1366. https://doi.org/10.1093/neuonc/nos216CrossRefPubMedPubMedCentral

110.

Yoo, H., Sohn, S., Nam, B. H., Min, H. S., Jung, E., Shin, S. H., et al. (2010). The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis. International Journal of Molecular Medicine, 26(1), 3–9. https://doi.org/10.3892/ijmm_00000427CrossRefPubMed

111.

Abraham, S., Hu, N., & Jensen, R. (2012). Hypoxia-inducible factor-1-regulated protein expression and oligodendroglioma patient outcome: Comparison with established biomarkers and preoperative UCSF low-grade scoring system. Journal of Neuro-oncology, 108(3), 459–468. https://doi.org/10.1007/s11060-012-0839-yCrossRefPubMed

112.

Jensen, R., & Lee, J. (2012). Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. Neurosurgery, 71(1), 146–156. https://doi.org/10.1227/NEU.0b013e3182567886CrossRefPubMed

113.

Sooman, L., Freyhult, E., Jaiswal, A., Navani, S., Edqvist, P. H., Ponten, F., et al. (2015). FGF2 as a potential prognostic biomarker for proneural glioma patients. Acta Oncologica, 54(3), 385–394. https://doi.org/10.3109/0284186X.2014.951492CrossRefPubMed

114.

Flynn, J. R., Wang, L., Gillespie, D. L., Stoddard, G. J., Reid, J. K., Owens, J., et al. (2008). Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer, 113(5), 1032–1042. https://doi.org/10.1002/cncr.23678CrossRefPubMed

115.

Preusser, M., Wolfsberger, S., Haberler, C., Breitschopf, H., Czech, T., Slavc, I., et al. (2005). Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathologica, 109(2), 211–216. https://doi.org/10.1007/s00401-004-0938-8CrossRefPubMed

116.

Couvelard, A., O’Toole, D., Turley, H., Leek, R., Sauvanet, A., Degott, C., et al. (2005). Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer, 92(1), 94–101. https://doi.org/10.1038/sj.bjc.6602245CrossRefPubMed

117.

Couvelard, A., O’Toole, D., Leek, R., Turley, H., Sauvanet, A., Degott, C., et al. (2005). Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology, 46(6), 668–676. https://doi.org/10.1111/j.1365-2559.2005.02160.xCrossRefPubMed

118.

Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., Kunz, P., et al. (2010). Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer, 116(22), 5179–5187. https://doi.org/10.1002/cncr.25481CrossRefPubMed

119.

Hiraoka, N., Ino, Y., Sekine, S., Tsuda, H., Shimada, K., Kosuge, T., et al. (2010). Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. British Journal of Cancer, 103(7), 1057–1065. https://doi.org/10.1038/sj.bjc.6605854CrossRefPubMedPubMedCentral

120.

Li, Y., Dong, M., Sheng, W., & Huang, L. (2016). Roles of carbonic anhydrase IX in development of pancreatic cancer. Pathology Oncology Research, 22(2), 277–286. https://doi.org/10.1007/s12253-015-9935-6CrossRefPubMed

121.

Schmitt, A. M., Schmid, S., Rudolph, T., Anlauf, M., Prinz, C., Kloppel, G., et al. (2009). VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine-Related Cancer, 16(4), 1219–1227. https://doi.org/10.1677/ERC-08-0297CrossRefPubMed

122.

Yu, M., Zhou, Q., Zhou, Y., Fu, Z., Tan, L., Ye, X., et al. (2015). Metabolic phenotypes in pancreatic cancer. PLoS ONE, 10(2), e0115153. https://doi.org/10.1371/journal.pone.0115153CrossRefPubMedPubMedCentral

123.

Trastour, C., Benizri, E., Ettore, F., Ramaioli, A., Chamorey, E., Pouyssegur, J., et al. (2007). HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. International Journal of Cancer, 120(7), 1451–1458. https://doi.org/10.1002/ijc.22436CrossRefPubMed

124.

Hussain, S. A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., et al. (2007). Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. British Journal of Cancer, 96(1), 104–109. https://doi.org/10.1038/sj.bjc.6603530CrossRefPubMedPubMedCentral

125.

Betof, A. S., Rabbani, Z. N., Hardee, M. E., Kim, S. J., Broadwater, G., Bentley, R. C., et al. (2012). Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. British Journal of Cancer, 106(5), 916–922. https://doi.org/10.1038/bjc.2012.32CrossRefPubMedPubMedCentral

126.

Aomatsu, N., Yashiro, M., Kashiwagi, S., Kawajiri, H., Takashima, T., Ohsawa, M., et al. (2014). Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. BMC Cancer, 14, 400. https://doi.org/10.1186/1471-2407-14-400CrossRefPubMedPubMedCentral

127.

Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmadi, A., et al. (2011). Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Research, 71(9), 3364–3376. https://doi.org/10.1158/0008-5472.CAN-10-4261CrossRefPubMed

128.

Tan, E. Y., Yan, M., Campo, L., Han, C., Takano, E., Turley, H., et al. (2009). The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer, 100(2), 405–411. https://doi.org/10.1038/sj.bjc.6604844CrossRefPubMedPubMedCentral

129.

Brennan, D. J., Jirstrom, K., Kronblad, A., Millikan, R. C., Landberg, G., Duffy, M. J., et al. (2006). CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clinical Cancer Research, 12(21), 6421–6431. https://doi.org/10.1158/1078-0432.CCR-06-0480CrossRefPubMed

130.

Generali, D., Fox, S. B., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., et al. (2006). Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer, 13(3), 921–930. https://doi.org/10.1677/erc.1.01216CrossRefPubMed

131.

Kyndi, M., Sorensen, F. B., Knudsen, H., Alsner, J., Overgaard, M., Nielsen, H. M., et al. (2008). Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of the DBCG82 b and c trials. Breast Cancer Research, 10(2), R24. https://doi.org/10.1186/bcr1981CrossRefPubMedPubMedCentral

132.

Neumeister, V. M., Sullivan, C. A., Lindner, R., Lezon-Geyda, K., Li, J., Zavada, J., et al. (2012). Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Research and Treatment, 136(1), 67–75. https://doi.org/10.1007/s10549-012-2232-0CrossRefPubMed

133.

Doyen, J., Trastour, C., Ettore, F., Peyrottes, I., Toussant, N., Gal, J., et al. (2014). Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochemical and Biophysical Research Communications, 451(1), 54–61. https://doi.org/10.1016/j.bbrc.2014.07.050CrossRefPubMed

134.

Pinheiro, C., Sousa, B., Albergaria, A., Paredes, J., Dufloth, R., Vieira, D., et al. (2011). GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histology and Histopathology, 26(10), 1279–1286. https://doi.org/10.14670/HH-26.1279CrossRefPubMed

135.

Garcia, S., Dales, J. P., Charafe-Jauffret, E., Carpentier-Meunier, S., Andrac-Meyer, L., Jacquemier, J., et al. (2007). Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Human Pathology, 38(6), 830–841. https://doi.org/10.1016/j.humpath.2006.11.015CrossRefPubMed

136.

Bane, A. L., Whelan, T. J., Pond, G. R., Parpia, S., Gohla, G., Fyles, A. W., et al. (2014). Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology, 25(5), 992–998. https://doi.org/10.1093/annonc/mdu090CrossRefPubMed

137.

Kim, H. M., Jung, W. H., & Koo, J. S. (2014). Site-specific metabolic phenotypes in metastatic breast cancer. Journal of Translational Medicine, 12, 354. https://doi.org/10.1186/s12967-014-0354-3CrossRefPubMedPubMedCentral

138.

Lancashire, L. J., Powe, D. G., Reis-Filho, J. S., Rakha, E., Lemetre, C., Weigelt, B., et al. (2010). A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Research and Treatment, 120(1), 83–93. https://doi.org/10.1007/s10549-009-0378-1CrossRefPubMed

139.

Kornegoor, R., Verschuur-Maes, A. H., Buerger, H., Hogenes, M. C., de Bruin, P. C., Oudejans, J. J., et al. (2012). Fibrotic focus and hypoxia in male breast cancer. Modern Pathology, 25(10), 1397–1404. https://doi.org/10.1038/modpathol.2012.101CrossRefPubMed

140.

Noh, S., Kim, J. Y., & Koo, J. S. (2014). Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. Tumour Biology, 35(8), 8179–8192. https://doi.org/10.1007/s13277-014-2103-xCrossRefPubMed

141.

Currie, M. J., Beardsley, B. E., Harris, G. C., Gunningham, S. P., Dachs, G. U., Dijkstra, B., et al. (2013). Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: Relationships with markers of tumor hypoxia and microvascularity. Human Pathology, 44(3), 402–411. https://doi.org/10.1016/j.humpath.2012.06.004CrossRefPubMed

142.

Deb, S., Johansson, I., Byrne, D., Nilsson, C., kConFab, I., Constable, L., et al. (2014). Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Mod Pathol, 27(9), 1223–1230. https://doi.org/10.1038/modpathol.2013.231CrossRefPubMed

143.

Beketic-Oreskovic, L., Ozretic, P., Rabbani, Z. N., Jackson, I. L., Sarcevic, B., Levanat, S., et al. (2011). Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2’-deoxyguanosine (8-OHdG) in breast cancer patients. Pathology Oncology Research, 17(3), 593–603. https://doi.org/10.1007/s12253-010-9355-6CrossRefPubMed

144.

Kaya, A. O., Gunel, N., Benekli, M., Akyurek, N., Buyukberber, S., Tatli, H., et al. (2012). Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. Journal of B.U.ON., 17(4), 663–668.PubMed

145.

Silva, P., Slevin, N. J., Sloan, P., Valentine, H., Ryder, D., Price, P., et al. (2010). Use of multiple biological markers in radiotherapy-treated head and neck cancer. Journal of Laryngology and Otology, 124(6), 650–658. https://doi.org/10.1017/S0022215110000228CrossRefPubMed

146.

Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, K., Pastorek, J., Wykoff, C. C., et al. (2001). Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clinical Cancer Research, 7(11), 3399–3403.PubMed

147.

Koukourakis, M. I., Bentzen, S. M., Giatromanolaki, A., Wilson, G. D., Daley, F. M., Saunders, M. I., et al. (2006). Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. Journal of Clinical Oncology, 24(5), 727–735. https://doi.org/10.1200/JCO.2005.02.7474CrossRefPubMed

148.

Bernstein, J. M., Andrews, T. D., Slevin, N. J., West, C. M., & Homer, J. J. (2015). Prognostic value of hypoxia-associated markers in advanced larynx and hypopharynx squamous cell carcinoma. The Laryngoscope, 125(1), E8-15. https://doi.org/10.1002/lary.24933CrossRefPubMed

149.

Choi, S. W., Kim, J. Y., Park, J. Y., Cha, I. H., Kim, J., & Lee, S. (2008). Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Human Pathology, 39(9), 1317–1322. https://doi.org/10.1016/j.humpath.2007.10.026CrossRefPubMed

150.

De Schutter, H., Landuyt, W., Verbeken, E., Goethals, L., Hermans, R., & Nuyts, S. (2005). The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer, 5, 42. https://doi.org/10.1186/1471-2407-5-42CrossRefPubMedPubMedCentral

151.

Douglas, C. M., Bernstein, J. M., Ormston, V. E., Hall, R. C., Merve, A., Swindell, R., et al. (2013). Lack of prognostic effect of carbonic anhydrase-9, hypoxia inducible factor-1alpha and bcl-2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy. Clinical Oncology (Royal College of Radiologists), 25(1), 59–65. https://doi.org/10.1016/j.clon.2012.07.004CrossRef

152.

Heo, K., Kim, Y. H., Sung, H. J., Li, H. Y., Yoo, C. W., Kim, J. Y., et al. (2012). Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncology, 48(6), 500–506. https://doi.org/10.1016/j.oraloncology.2011.12.015CrossRefPubMed

153.

Kim, S. J., Shin, H. J., Jung, K. Y., Baek, S. K., Shin, B. K., Choi, J., et al. (2007). Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Japanese Journal of Clinical Oncology, 37(11), 812–819. https://doi.org/10.1093/jjco/hym121CrossRefPubMed

154.

Perez-Sayans, M., Suarez-Penaranda, J. M., Pilar, G. D., Supuran, C. T., Pastorekova, S., Barros-Angueira, F., et al. (2012). Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients. Journal of Oral Pathology and Medicine, 41(9), 667–674. https://doi.org/10.1111/j.1600-0714.2012.01147.xCrossRefPubMed

155.

Wachters, J. E., Schrijvers, M. L., Slagter-Menkema, L., Mastik, M., de Bock, G. H., Langendijk, J. A., et al. (2013). Prognostic significance of HIF-1a, CA-IX, and OPN in T1–T2 laryngeal carcinoma treated with radiotherapy. The Laryngoscope, 123(9), 2154–2160. https://doi.org/10.1002/lary.23831CrossRefPubMed

156.

Eriksen, J. G., Overgaard, J., Danish, H., Neck Cancer Study, G. (2007). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study. Radiother Oncol, 83(3), 383–388. https://doi.org/10.1016/j.radonc.2007.05.009CrossRefPubMed

157.

Le, Q. T., Shi, G., Cao, H., Nelson, D. W., Wang, Y., Chen, E. Y., et al. (2005). Galectin-1: A link between tumor hypoxia and tumor immune privilege. Journal of Clinical Oncology, 23(35), 8932–8941. https://doi.org/10.1200/JCO.2005.02.0206CrossRefPubMed

158.

Nordsmark, M., Eriksen, J. G., Gebski, V., Alsner, J., Horsman, M. R., & Overgaard, J. (2007). Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and Oncology, 83(3), 389–397. https://doi.org/10.1016/j.radonc.2007.04.021CrossRefPubMed

159.

Winter, S. C., Shah, K. A., Han, C., Campo, L., Turley, H., Leek, R., et al. (2006). The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer, 107(4), 757–766. https://doi.org/10.1002/cncr.21983CrossRefPubMed

160.

Koukourakis, M. I., Giatromanolaki, A., Danielidis, V., & Sivridis, E. (2008). Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. International Journal of Radiation Biology, 84(1), 47–52. https://doi.org/10.1080/09553000701616114CrossRefPubMed

161.

Kondo, Y., Yoshikawa, K., Omura, Y., Shinohara, A., Kazaoka, Y., Sano, J., et al. (2011). Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma. Oncology Reports, 25(5), 1227–1233. https://doi.org/10.3892/or.2011.1216CrossRefPubMed

162.

Brockton, N., Dort, J., Lau, H., Hao, D., Brar, S., Klimowicz, A., et al. (2011). High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. International Journal of Radiation Oncology Biology Physics, 80(1), 249–257. https://doi.org/10.1016/j.ijrobp.2010.11.059CrossRefPubMed

163.

Brockton, N. T., Klimowicz, A. C., Bose, P., Petrillo, S. K., Konno, M., Rudmik, L., et al. (2012). High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma. Oral Oncology, 48(7), 615–622. https://doi.org/10.1016/j.oraloncology.2012.01.018CrossRefPubMed

164.

Zheng, G., Peng, C., Jia, X., Gu, Y., Zhang, Z., Deng, Y., et al. (2015). ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH. Molecular Cancer, 14, 84. https://doi.org/10.1186/s12943-015-0357-6CrossRefPubMedPubMedCentral

165.

Sakata, K., Someya, M., Nagakura, H., Nakata, K., Oouchi, A., Takagi, M., et al. (2008). Brachytherapy for oral tongue cancer: An analysis of treatment results with various biological markers. Japanese Journal of Clinical Oncology, 38(6), 402–407. https://doi.org/10.1093/jjco/hyn050CrossRefPubMed

166.

Chen, Y., Li, X., Wu, S., Xu, G., Zhou, Y., Gong, L., et al. (2014). Expression of HIF-1alpha and CAIX in nasopharyngeal carcinoma and their correlation with patients’ prognosis. Medical Oncology, 31(12), 304. https://doi.org/10.1007/s12032-014-0304-1CrossRefPubMed

167.

Hwa, J. S., Kwon, O. J., Park, J. J., Woo, S. H., Kim, J. P., Ko, G. H., et al. (2015). The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 272(10), 2953–2959. https://doi.org/10.1007/s00405-014-3254-5CrossRefPubMed

168.

Kwon, O. J., Park, J. J., Ko, G. H., Seo, J. H., Jeong, B. K., Kang, K. M., et al. (2015). HIF-1alpha and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma. Head and Neck, 37(4), 505–510. https://doi.org/10.1002/hed.23620CrossRefPubMed

169.

Han, M. W., Lee, H. J., Cho, K. J., Kim, J. S., Roh, J. L., Choi, S. H., et al. (2012). Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. Head and Neck, 34(10), 1395–1402. https://doi.org/10.1002/hed.21945CrossRefPubMed

170.

Roh, J. L., Cho, K. J., Kwon, G. Y., Choi, S. H., Nam, S. Y., & Kim, S. Y. (2008). Prognostic values of pathologic findings and hypoxia markers in 21 patients with salivary duct carcinoma. Journal of Surgical Oncology, 97(7), 596–600. https://doi.org/10.1002/jso.21045CrossRefPubMed

171.

Roh, J. L., Cho, K. J., Kwon, G. Y., Ryu, C. H., Chang, H. W., Choi, S. H., et al. (2009). The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncology, 45(1), 63–68. https://doi.org/10.1016/j.oraloncology.2008.03.017CrossRefPubMed

172.

Yang, J. S., Lin, C. W., Chuang, C. Y., Su, S. C., Lin, S. H., & Yang, S. F. (2015). Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma. Tumour Biology, 36(12), 9517–9524. https://doi.org/10.1007/s13277-015-3692-8CrossRefPubMed

173.

Eckert, A. W., Lautner, M. H., Schutze, A., Bolte, K., Bache, M., Kappler, M., et al. (2010). Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. Journal of Oral Pathology and Medicine, 39(4), 313–317. https://doi.org/10.1111/j.1600-0714.2009.00829.xCrossRefPubMed

174.

Jonathan, R. A., Wijffels, K. I., Peeters, W., de Wilde, P. C., Marres, H. A., Merkx, M. A., et al. (2006). The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiotherapy and Oncology, 79(3), 288–297. https://doi.org/10.1016/j.radonc.2006.04.008CrossRefPubMed

175.

Rademakers, S. E., Hoogsteen, I. J., Rijken, P. F., Oosterwijk, E., Terhaard, C. H., Doornaert, P. A., et al. (2013). Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiotherapy and Oncology, 108(3), 517–522. https://doi.org/10.1016/j.radonc.2013.04.022CrossRefPubMed

176.

Gilchrist, K. W., Gray, R., Fowble, B., Tormey, D. C., Taylor, S. G., & t. (1993). Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: A 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. Journal of Clinical Oncology, 11(10), 1929–1935. https://doi.org/10.1200/JCO.1993.11.10.1929CrossRefPubMed

177.

Ord, J. J., Agrawal, S., Thamboo, T. P., Roberts, I., Campo, L., Turley, H., et al. (2007). An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. Journal of Urology, 178(2), 677–682. https://doi.org/10.1016/j.juro.2007.03.112CrossRefPubMed

178.

Ramos-Vara, J. A., & Miller, M. A. (2014). When tissue antigens and antibodies get along: Revisiting the technical aspects of immunohistochemistry–The red, brown, and blue technique. Veterinary Pathology, 51(1), 42–87. https://doi.org/10.1177/0300985813505879CrossRefPubMed

179.

Hartling, L., Milne, A., Hamm, M. P., Vandermeer, B., Ansari, M., Tsertsvadze, A., et al. (2013). Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. Journal of Clinical Epidemiology, 66(9), 982–993. https://doi.org/10.1016/j.jclinepi.2013.03.003CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Biography—Anna Sebestyén, Ph.D.

Pancreatic cancer: branched-chain amino acids as putative key metabolic regulators?

Tumor metabolism: metabolic alterations and heterogeneity in cancer progression

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Model systems in SDHx-related pheochromocytoma/paraganglioma

What do cellular responses to acidity tell us about cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer